Bear Stearns maintains MedImmune at outperform

MedImmune Inc. was kept at its outperform rating by Bear Stearns analyst Mark Schoenebaum on an expected 12% benefit on Synagis sales from pricing, more if population growth is factored in. While the company launched he liquid version of Synagis earlier this year, it did not take a price increase. Instead, MedImmune raised the price of Synagis 9.7%, according to the analyst. Shares of the Gaithersburg, Md.-based biotechnology company were up 10 cents, or 0.39%, at $25.48, on volume of 2,104,102 shares versus the three-month running average of 2,984,630 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.